Miromatrix Presenting at the 2023 American Transplant Congress
30 Maggio 2023 - 10:08PM
Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company
pioneering a novel technology for bioengineering fully
transplantable organs to help save and improve patients' lives,
announced it will be presenting at the upcoming 2023 American
Transplant Congress ("ATC") held on June 3rd to June 7th, 2023 in
San Diego, California.
"We are proud to have a meaningful presence at
ATC this year," said Jeff Ross, Ph.D., Miromatrix CEO. "ATC is the
ideal venue for us to showcase some of the important advancements
we have made with our bioengineered organs to leaders in the
transplant community."
Miromatrix had the following posters accepted
for presentation at ATC:
- Manufacturing and Functional Characterization of Bioengineered
Liver Grafts for Extracorporeal Liver Assistance in Acute Liver
Failure
- Initial Preclinical Evaluation of a Bioengineered Kidney
- Podocyte Differentiation of Primary Human Glomerular Outgrowth
Cells
About MiromatrixMiromatrix Medical Inc. is
a life sciences company pioneering a novel technology for
bioengineering fully transplantable human organs to help save and
improve patients' lives. The Company has developed a proprietary
perfusion technology platform for bioengineering organs that it
believes will efficiently scale to address the shortage of
available human organs. The Company's initial development focus is
on human livers and kidneys. For more information,
visit miromatrix.com.
Investor ContactGreg Chodaczek347-620-7010
ir@miromatrix.com
Media Contact:press@miromatrix.com
Grafico Azioni MiroMatrix Medical (NASDAQ:MIRO)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni MiroMatrix Medical (NASDAQ:MIRO)
Storico
Da Set 2023 a Set 2024